Brentuximab: is it time for a new “B” in ABVD?

Stephens, Deborah M.

doi:10.1182/blood-2017-08-798553

Blood

2017

DOI: 10.1182/blood-2017-08-798553

|View full text |Cite

Brentuximab: is it time for a new “B” in ABVD?

Deborah M. Stephens

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2018

2022

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly anti CD30 Brentuximab Vedotin (BV) became a major success story in relapse-refractory Hodgkins disease. BV now threatens to replace the conventional Bleomycin, ''B'' of ABVD, a drug attributed to the most sinister long term pulmonary toxicity of ABVD, as a first line therapy [4].…”

mentioning

confidence: 99%

Lymphoma in ‘India’ at the Dawn of Targeted Therapies

Kapoor

Kumar

2018

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

mentioning

confidence: 99%

Lymphoma in ‘India’ at the Dawn of Targeted Therapies

Kapoor

Kumar

2018

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

Evolution of therapy for limited stage diffuse large B-cell lymphoma

Rojek

Smith

2022

Blood Cancer J.

View full text Add to dashboard Cite

Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma (NHL), with limited-stage DLBCL defined as stage I or II disease. Risk stratification, initial treatment options, and relapse patterns are distinct from advanced-stage DLBCL, but there is limited data on the impact of biologic features on outcome. Patients have excellent outcomes, with ~90% survival at 2 years. Over the past several years, sequential prospective trials and large registry studies have evaluated the optimal number of chemotherapy cycles and implemented PET-adapted approaches to reduce the need for radiotherapy. Special consideration must still be given to cases of bulky disease, extranodal disease, fully resected scenarios, and adverse biologic features such as high-grade B-cell lymphoma with double/triple hit rearrangements. This review presents the evolution of a modern management approach, with a discussion of recent treatment-defining studies.

show abstract

Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia

Mueller¹,

Waldron

Grupp

et al. 2018

Clinical Cancer Research

187

196

View full text Add to dashboard Cite

Tisagenlecleucel is an anti-CD19 chimeric antigen receptor (CAR19) T-cell therapy approved for the treatment of children and young adults with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL). We evaluated the cellular kinetics of tisagenlecleucel, the effect of patient factors, humoral immunogenicity, and manufacturing attributes on its kinetics, and exposure-response analysis for efficacy, safety and pharmacodynamic endpoints in 79 patients across two studies in pediatric B-ALL (ELIANA and ENSIGN). Using quantitative polymerase chain reaction to quantify levels of tisagenlecleucel transgene, responders ( = 62) had ≈2-fold higher tisagenlecleucel expansion in peripheral blood than nonresponders ( = 8; 74% and 104% higher geometric mean Cmax and AUC0-28d, respectively) with persistence measurable beyond 2 years in responding patients. Cmax increased with occurrence and severity of cytokine release syndrome (CRS). Tisagenlecleucel continued to expand and persist following tocilizumab, used to manage CRS. Patients with B-cell recovery within 6 months had earlier loss of the transgene compared with patients with sustained clinical response. Clinical responses were seen across the entire dose range evaluated (patients ≤50 kg: 0.2 to 5.0 × 10/kg; patients >50 kg: 0.1 to 2.5 × 10 CAR-positive viable T cells) with no relationship between dose and safety. Neither preexisting nor treatment-induced antimurine CAR19 antibodies affected the persistence or clinical response. Response to tisagenlecleucel was associated with increased expansion across a wide dose range. These results highlight the importance of cellular kinetics in understanding determinants of response to chimeric antigen receptor T-cell therapy.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Brentuximab: is it time for a new “B” in ABVD?

Cited by 4 publications

References 9 publications

Lymphoma in ‘India’ at the Dawn of Targeted Therapies

Lymphoma in ‘India’ at the Dawn of Targeted Therapies

Evolution of therapy for limited stage diffuse large B-cell lymphoma

Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia

Contact Info

Product

Resources

About